Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 8 and 18 years-old~* Diagnosed with Functional Abdominal Pain using the Rome III Criteria must include all\* of the following:~  1. Episodic or continuous abdominal pain~ 2. Insufficient criteria for other FGIDs~ 3. No evidence of an inflammatory, anatomic, metabolic, or neoplastic process that explains the subject's symptoms~     * Criteria fulfilled at least once per week for at least 2 months prior to diagnosis~* Written informed consent obtained from the patient/guardian before the initiation of any study-specific procedures~Exclusion Criteria:~* Age \< 8 years-old or Age \>18 years-old~* Child or parent are non-English speakers~* Child is using other CNS depressants (cyproheptadine causes drowsiness, and may enhance the adverse/toxic effect of other CNS Depressants e.g. opioids, barbiturates, Droperidol, Hydroxyzine, Alcohol)(29)~* Child has a history of hypersensitivity to Cyproheptadine products~* Child is currently using monoamine oxidase inhibitor (MAOI e.g. Nardil, Marplan, Parnate) (can cause a prolonged or intensified anticholinergic effect)~* Child was treated with Cyproheptadine in the past 4 weeks~* Child is currently using anticholinergic (can cause an additive anticholinergic effect e.g. Pramlintide)~* Concomitant SSRI use ( being a serotonin antagonist, may oppose effects)~* Concomitant use of Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine~* Concomitant use of Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central) and vice versa.~* Child has a personal history of glaucoma~* Child has asthma (can cause thickening of bronchial secretions) (27,28)~* History of liver dysfunction/disease (can cause hepatitis)~* History of cardiac disease (not specific to Cyproheptadine, antihistamines have been associated with hypotension, palpitations, tachycardia and arrhythmias) (28,29).~* Females who are known to be pregnant will also be excluded. All females who are of child bearing age, or are already menstruating will perform a urine pregnancy test before enrolling.~* Any children who have difficulties swallowing tablets will receive teaching on how to swallow tablets. If they are still unable to do so, they will not participate in the study.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Cyproheptadine first then Placebo (Type: EXPERIMENTAL): 4 weeks of cyproheptadine or placebo with crossover to the other
- Sugar Pill first then Cyprotheptadine (Type: EXPERIMENTAL): 4 weeks of cyproheptadine or placebo with crossover to the other

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues